AAV vector is derived from nonpathogenic virus and has a number of attractive features as a vector for human gene transfer including safety, broad tissue speciˆcity, and low immunogenicity following gene transfer. Moreover, persistent transgene expression (for years) was demonstrated in multiple animal experiments. For these reasons, applications to a wide spectrum of diseases are expected, and several clinical trials have been conducted. Although it is too early to conclude the outcome, the e‹cacy of treatment was not su‹ciently substantiated in most of the trials despite conˆrming the safety of the vector. These results are primarily due to low levels of transgene expression. One of the approaches to improve this situation is the use of alternative serotypes of AAV. Traditionally, serotype 2 was considered to be a prototype of AAV, and the majority of studies including human clinical trials have been conducted using this serotype. On the other hand, there areˆve``classical'' serotypes, and several have been additionally discovered from tissues of primates including humans. These serotypes are considered to be valuable resources for vector development to overcome the shortcomings of serotype 2. This review focuses on the diŠerence in expression levels and tissue speciˆcity of various serotype-derived vectors and summarizes current status in the treatment of candidate diseases.
. AAV Vector Production and Puriˆcation Strategies
The most popular method for AAV vector production has been plasmid transfection using Calcium-phosphate. HEK293 cells are preferred because of the high e‹ciency of transfection which leads to outstanding vector production. After 2-3 days, the cells are harvested and destroyed for e‹cient vector release. Then the vectors are puriˆed through density gradient and/or columns. 
